How is metastatic hormone-sensitive prostate cancer treated?
Time of Update: 2021-04-13
The data showed that enzalutamide combined with androgen deprivation therapy (ADT) significantly reduced the risk of radiography or death in mHSPC patients by 61% compared with placebo combined with ADT (P <0.
"Where to go" for bladder outlet obstruction in patients with benign prostatic hyperplasia?
Time of Update: 2021-03-25
By blocking the binding of α1A adrenergic receptors and norepinephrine, Serodosin relaxes the smooth muscles of the bladder and prostate, relieves bladder outlet dynamic obstruction, and effectively improves lower urinary tract symptoms caused by BPH4.
JAMA Neurol: Benign prostate hyperplies may prevent Parkinson's disease
Time of Update: 2021-02-10
, and the Truven queue (short-term: HR=0.70; medium-term: HR=0.58; long-term: HR=0.46) showed similar results. study found that in patients with benign prostate hyperplosomes, parkinson's risk decreased in people treated with pyridone.
J Clin Oncol: Capivasertib combined with Dositassai and Pernisone to treat metastatic desopathic prostate cancer
Time of Update: 2021-01-01
results showed that for mCRPC patients, adding Capivasertib to chemotherapy did not further improve the patient's cPFS, regardless of the status of the PI3K/AKT/PTEN signal path.
Lancet: The effect of assisted radiotherapy on event-free survival in prostate cancer patients immediately after root-and-treat surgery.
Time of Update: 2020-10-12
Recently, researchers conducted a randomized controlled study to compare the efficacy of anthractic post-prostatectomy assisted radiotherapy or early remedial radiotherapy in patients with local or local advanced prostate cancer.
Analysis of the quality of life of patients with metastatic desopathic prostate cancer treated with kabatha.
Time of Update: 2020-10-09
In the CARD study, cabazitaxel (cabataxel) significantly extended the progressive survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors compared to abitor or erythromycin.
Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.
Time of Update: 2020-10-04
In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
To treat prostate hyperplasia, you need to know these drugs.
Time of Update: 2020-08-06
pain complications caused by tamastasamine was significantly higher than that of finasteride. usage: finasteride 5 mg, 1 time a day; M receptor antagonists commonly used drugs: Totrodine, oxibnon (non-selective M receptor antagonists
Australian scientists have developed new blood tests to help treat invasive prostate cancer.
Time of Update: 2020-07-17
This article is original for the Translational Medicine Network, reproduced please note the source cathy introduction: prostate cancer (prostate cancer, PCa) is a common malignant tumor in older men, in Europe and the United States, the incidence
The effect of plastic self-elastic stent in treating benign lesions of esophagus is worrying
Time of Update: 2020-07-02
But studies such as Holm, a hospital , but plastic self-elastic stents treat healthy lesions in the esophagus have a higher rate of displacement and a low rate of improvement in long-term symptoms.
Study finds key molecular switches for treating prostate cancer
Time of Update: 2020-06-09
The newsletter's author, Dr. Chawnshang Chang, and his colleagues described how enzalutamide inadvertently caused harmful transformations, and they believe they have found a way to stop the conversion, at least in mice. The study, led by Jie Luo
Target AVPR1A protein is expected to treat aggressive prostate cancer
Time of Update: 2020-06-08
in addition, , treating CRPC cells with AVPR1A ligand --- arginine pressurizin (AVP) --- activates ERK and CREB, a known promoter of prostate cancer progression.
NEJM: Enmeluamine used to treat desomnivoic prostate cancer
Time of Update: 2020-06-05
studies suggest that the combination of enmelua androgen deprivation therapy can prolong the total survival of patients with non-metastatic, de-resistant prostate cancer.
New combination therapy could safely and effectively treat advanced prostate cancer
Time of Update: 2020-06-02
Prostate cancer is the most common cancer in U.S. men except skin cancer. According to the American Cancer Society, about 175,000 new prostate cancer patients are diagnosed each year in the United States, and more than 315,000 men die from prostate
FDA approves darolutamide for treating men with non-metastatic resistant prostate cancer
Time of Update: 2020-06-02
Dr. Matthew Smith, director of the Urinary Malignancy Malignancy Program at Massachusetts General Hospital Cancer Center, said the approval marks an important new option for prostate cancer groups.
CAR-T cell therapy clinical trial launched to treat advanced prostate cancer
Time of Update: 2020-06-01
Studies have shown that immunotherapy for PSCA is an effective way to treat advanced and hormone-dependent prostate cancer, which can inhibit tumor formation and growth, reduce metastasis and prolong patient survival through active and passive immunity.
NEJM: Olapani Treats Metastatic Drug-resistant Prostate Cancer
Time of Update: 2020-05-29
Multiple cancers are associated with polysephonic (diphosphate adenosine-ribose) polymerase (PARP), and researchers recently looked at the effectiveness of Orapani's treatment for prostate cancer this study
FDA approves AstraZeneca/Merck's PARP inhibitor Lynparza to treat prostate cancer
Time of Update: 2020-05-29
AstraZeneca and Merck announced that the FDA has approved its PARP inhibitor Lynparza (olaparib) for the treatment of patients with homogenous resusandive (HRR) gene mutations, and the progression of the disease after treatment
MAJOR ADVANCES IN NEJM: BREAST CANCER DRUGS TO TREAT PROSTATE CANCER ARE MORE EFFECTIVE THAN STANDARD THERAPIES!
Time of Update: 2020-05-28
researchers now hope that within the next two years, Olapani could be used to treat patients with advanced prostate cancer with defective DNA repair genes.
Olapari gets FDA approval to treat prostate cancer!
Time of Update: 2020-05-20
AstraZeneca and Merck announced today, Lynparza (olaparib) has been approved by the FDA for metastatic castration has homologous recombination repair (HRR) gene mutations resistant prostate cancer (mCRPC) patients.